Mega Lifesciences Public Company Limited (MEGA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mega Lifesciences Public Company Limited (MEGA) has a cash flow conversion efficiency ratio of 0.046x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (฿461.26 Million ≈ $14.38 Million USD) by net assets (฿9.95 Billion ≈ $310.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Mega Lifesciences Public Company Limited for the company's overall valuation and market capitalisation.
Mega Lifesciences Public Company Limited - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Mega Lifesciences Public Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mega Lifesciences Public Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mega Lifesciences Public Company Limited ranked by their cash flow conversion efficiency. Explore how high is Mega Lifesciences Public Company Limited's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Silicon Integrated Systems Corp
TW:2363
|
-0.001x |
|
Lontium Semiconductor Corp. A
SHG:688486
|
N/A |
|
Shenzhen Comix Group Co Ltd
SHE:002301
|
0.017x |
|
Yulon Motor Co Ltd
TW:2201
|
-0.013x |
|
Upbound Group Inc.
NASDAQ:UPBD
|
0.168x |
|
Yotrio Group Co Ltd
SHE:002489
|
-0.246x |
|
Pegavision
TW:6491
|
0.067x |
|
ZhuZhou QianJin Pharmaceutical Co Ltd
SHG:600479
|
0.084x |
Annual Cash Flow Conversion Efficiency for Mega Lifesciences Public Company Limited (2011–2024)
The table below shows the annual cash flow conversion efficiency of Mega Lifesciences Public Company Limited from 2011 to 2024. View MEGA share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ฿9.88 Billion ≈ $307.85 Million |
฿2.40 Billion ≈ $74.85 Million |
0.243x | +17.40% |
| 2023-12-31 | ฿9.30 Billion ≈ $289.94 Million |
฿1.93 Billion ≈ $60.05 Million |
0.207x | -8.96% |
| 2022-12-31 | ฿8.78 Billion ≈ $273.56 Million |
฿2.00 Billion ≈ $62.23 Million |
0.227x | -33.05% |
| 2021-12-31 | ฿8.03 Billion ≈ $250.14 Million |
฿2.73 Billion ≈ $84.99 Million |
0.340x | +45.53% |
| 2020-12-31 | ฿6.98 Billion ≈ $217.53 Million |
฿1.63 Billion ≈ $50.79 Million |
0.233x | -3.57% |
| 2019-12-31 | ฿6.18 Billion ≈ $192.47 Million |
฿1.50 Billion ≈ $46.60 Million |
0.242x | +50.75% |
| 2018-12-31 | ฿5.72 Billion ≈ $178.42 Million |
฿919.36 Million ≈ $28.66 Million |
0.161x | -9.14% |
| 2017-12-31 | ฿5.24 Billion ≈ $163.46 Million |
฿927.00 Million ≈ $28.89 Million |
0.177x | -34.37% |
| 2016-12-31 | ฿4.68 Billion ≈ $145.87 Million |
฿1.26 Billion ≈ $39.29 Million |
0.269x | +91.67% |
| 2015-12-31 | ฿4.33 Billion ≈ $135.11 Million |
฿609.12 Million ≈ $18.99 Million |
0.141x | -8.98% |
| 2014-12-31 | ฿3.98 Billion ≈ $124.00 Million |
฿614.22 Million ≈ $19.14 Million |
0.154x | +22.40% |
| 2013-12-31 | ฿3.69 Billion ≈ $115.09 Million |
฿465.77 Million ≈ $14.52 Million |
0.126x | -40.02% |
| 2012-12-31 | ฿1.63 Billion ≈ $50.69 Million |
฿342.02 Million ≈ $10.66 Million |
0.210x | +3.97% |
| 2011-12-31 | ฿1.32 Billion ≈ $41.09 Million |
฿266.67 Million ≈ $8.31 Million |
0.202x | -- |
About Mega Lifesciences Public Company Limited
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provi… Read more